Therapeutic potential of neurotrophic factors in Alzheimer’s Disease

Introduction Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia among the elderly population. AD is accompanied with the dysregulation of specific neurotrophic factors (NTFs) and their receptors, which plays a critical role in neuronal deg...

Full description

Saved in:
Bibliographic Details
Published in:Molecular biology reports 2022-03, Vol.49 (3), p.2345-2357
Main Authors: Nasrolahi, Ava, Javaherforooshzadeh, Fatemeh, Jafarzadeh-Gharehziaaddin, Mohsen, Mahmoudi, Javad, Asl, Khadijeh Dizaji, Shabani, Zahra
Format: Article
Language:English
Subjects:
Aged
Alzheimer Disease - drug therapy
Alzheimer Disease - metabolism
Alzheimer's disease
Animal Anatomy
Animal Biochemistry
Biomedical and Life Sciences
Cell death
Cognitive ability
Dementia disorders
Glial cells
Growth factors
Histology
Humans
Life Sciences
Morphology
Nerve Growth Factors - metabolism
Nerve Growth Factors - therapeutic use
Neurodegeneration
Neurodegenerative diseases
Neuronal-glial interactions
Neurotrophic factors
Older people
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia among the elderly population. AD is accompanied with the dysregulation of specific neurotrophic factors (NTFs) and their receptors, which plays a critical role in neuronal degeneration. NTFs are small proteins with therapeutic potential for human neurodegenerative diseases. These growth factors are categorized into four families: neurotrophins, neurokines, the glial cell line-derived NTF family of ligands, and the newly discovered cerebral dopamine NTF/mesencephalic astrocyte-derived NTF family. NTFs are capable of preventing cell death in degenerative conditions and can increase the neuronal growth and function in these disorders. Nevertheless, the adverse side effects of NTFs delivery and poor diffusion of these factors in the brain restrict the efficacy of NTFs therapy in clinical situations. Materials and methods In this review, we focus on the current advances in the use of NTFs to treat AD and summarize previous experimental and clinical studies for supporting the protective and therapeutic effects of these factors. Conclusion Based on reports, NTFs are considered as new and promising candidates for treating AD and AD-associated cognitive impairment.
ISSN:0301-4851
1573-4978
DOI:10.1007/s11033-021-06968-9